mitochondrial complex V (ATP synthase) deficiency, nuclear type 1

ORPHA: 254913

Overview

mitochondrial metabolism disease that has material basis in mutation in the ATPAF2 gene on chromosome 17p11

Available Treatments (0)

No treatments linked yet

Clinical trials or compassionate use may be available — consult a specialist.

Clinical Presentation

Signs and symptoms associated with mitochondrial complex V (ATP synthase) deficiency, nuclear type 1, sourced from HPO and Orphanet clinical annotations.

SeizureAtaxiaHypotoniaMotor delayEncephalopathyMuscle weaknessHypertrophic cardiomyopathyDilated cardiomyopathyHyperammonemiaRespiratory distressLactic acidosisHyperalaninemia3-Methylglutaconic aciduriaPeripheral neuropathyArrhythmiaNeurodevelopmental delayRenal hypoplasiaHypogonadismMicrocephalySensorineural hearing impairmentStrabismusPtosisRod-cone dystrophyCataractBlindnessNystagmusOptic atrophyHypothyroidismLethargySpastic paraplegiaDysarthriaCerebellar atrophyDystoniaCerebral cortical atrophyHepatomegalyTetraplegiaExercise intoleranceShort statureMyoclonic seizureOphthalmoplegia

Classification & Codes

Orphanet Code

ORPHA:254913
mitochondrial complex V (ATP synthase) deficiency, nuclear type 1
OrphanetORPHA:254913
Treatments0 drug(s)
Symptoms on record40 signs
Statuspublished
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO
mitochondrial complex V (ATP synthase) deficiency, nuclear type 1 | OrphanDrug